Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Harold M. Weintraub
Weintraub died on March 28, 1995 in Seattle, Washington, as a result of complications from glioblastoma multiforme, a very aggressive and fast-growing brain tumor. He had only been diagnosed six months beforehand, undergoing neurosurgery in an attempt to curb its spread. Weintraub was survived by his wife and two sons. In the years that followed, several items were created in his memory: